It is estimated that eight million people have the disease, but that number is growing as global warming is allowing it to rapidly spread to Europe and North America. People with the disease endure cardio and gastrointestinal complications for decades and like most tropical diseases, pharmaceutical companies are not incentivised to work on effective treatments.

The three-year research project will target the synthesis of libraries of novel fluorinated compounds for testing against the disease.